Enclomiphene vs TRT, and TRT with HCG: how the fertility options compare

Men who want to treat low testosterone and still keep the door open to children usually end up comparing three options: testosterone on its own, TRT with HCG, or enclomiphene instead of testosterone. If your first question is simply whether testosterone hurts fertility, start with our explainer on whether TRT causes infertility; if you are still working out whether low testosterone is the problem at all, see our guide to low testosterone symptoms. This page picks up from there and compares the options men discuss, on what the published studies actually measured. None of it is a prediction of your own result, which only a licensed provider can judge from your labs and history.

Enclomiphene vs TRT: what is the difference?

The difference is direction. Testosterone therapy adds testosterone from outside the body, which tells the brain to stop sending the LH and FSH signals the testes need, so sperm production falls (Crosnoe et al., Transl Androl Urol 2013). Enclomiphene raises a man’s own LH and FSH instead, so the testes make more testosterone and keep making sperm (Rodriguez et al., Expert Opin Pharmacother 2016).

Enclomiphene is a selective estrogen receptor modulator and the trans isomer of clomiphene. It works at the hypothalamus by blocking the estrogen feedback that normally throttles gonadotropin release; with that brake removed, the pituitary sends more LH and FSH to the testes (Clomiphene, StatPearls; Rodriguez et al., 2016).

The best head-to-head data come from the drug’s own development program. In a randomized phase II trial against a 1% testosterone gel, enclomiphene raised morning testosterone to levels similar to the gel, and FSH and LH rose while sperm counts were conserved (Wiehle et al., Fertil Steril 2014). Two parallel randomized, double-blind phase III trials then compared two enclomiphene doses with a 1.62% testosterone gel in overweight men aged 18 to 60 with secondary hypogonadism. After 16 weeks, testosterone rose in every group, but LH and FSH went up on enclomiphene and down on the gel, and enclomiphene kept sperm concentration in the normal range while the gel group showed “a marked reduction in spermatogenesis” (Kim et al., BJU Int 2016). The catch is that it depends on testes that can still respond to the extra signal, which is part of the clinical judgment about who suits it.

How does testosterone shut down sperm production?

Sperm production depends on a very high concentration of testosterone inside the testes, and that local supply collapses when the brain stops sending its signals. LH drives the testes to make testosterone locally and FSH supports the cells that mature sperm (Crosnoe et al., 2013). The concentration inside the testes is roughly fifty to a hundred times the level measured in blood, and spermatogenesis needs that gradient (McBride & Coward, Asian J Androl 2016).

Supplemental testosterone raises the blood level but does nothing for the supply inside the testes. Through normal negative feedback, the higher blood level cuts LH and FSH, so the testes lose the signal to make both local testosterone and sperm (Crosnoe et al., 2013). In a WHO testosterone-based male contraception trial of 271 men reviewed in that analysis, about two thirds (65%) had reached azoospermia (no sperm in the ejaculate) after six months, at a mean of about 120 days (WHO trial data, in Crosnoe et al.). Every fertility-preserving strategy is built to get around this: keep an LH-like signal reaching the testes, or avoid removing it in the first place.

What does TRT with HCG do for fertility?

TRT with HCG keeps testosterone therapy and adds human chorionic gonadotropin, which closely mimics LH, so the testes keep getting the signal that supplemental testosterone switches off. In small studies, that combination maintained testosterone inside the testes and kept semen quality steady.

The mechanism evidence is a randomized, placebo-controlled study of 29 healthy men whose own hormones were suppressed with testosterone for three weeks and who also received either placebo or one of three low doses of HCG. Testosterone inside the testes rose with the HCG dose, and the higher doses kept it near baseline despite profound suppression of the men’s own LH (Coviello et al., J Clin Endocrinol Metab 2005).

The clinical evidence for TRT and HCG together is a retrospective review of 26 hypogonadal men, mean age about 36, who used testosterone injections or gel with low-dose HCG. Over an average follow-up of about six months, semen parameters did not change, no man became azoospermic, and 9 of the 26 men contributed to a pregnancy with their partner (Hsieh et al., J Urol 2013). The same authors note that testosterone therapy alone leads to azoospermia in about 40% of patients, which is the problem HCG is meant to solve. That is encouraging but small, and a retrospective series cannot rule out that the men who stayed on the protocol differed from those who did not.

Kisspeptin, a peptide that acts further upstream on the same LH signal, is sometimes floated online as a replacement for HCG. Its human data so far are small, short infusion studies, and it is not among the fertility options the AUA lists; our page on whether peptides raise testosterone walks through that evidence. PeptideAgent’s hCG vs kisspeptin-10 comparison comes down on hCG’s side for a related reason: kisspeptin-10’s small randomized studies measured hormone responses, and none has tested it for a clinical endpoint.

Enclomiphene alone vs TRT alone vs TRT plus HCG

The three options differ less in what they do to blood testosterone than in what they do to LH, FSH and sperm, and in how much evidence sits behind each. The table summarizes what the studies cited on this page measured; evidence levels are stated in words.

None of these is a default. The choice comes from baseline labs, age, how much fertility matters and on what timeline, and how the body responds once treatment starts. It also helps to separate two goals that often get blurred: relieving low-testosterone symptoms, and keeping fertility intact. TRT alone handles the first well and the second poorly, which is exactly the gap HCG and enclomiphene are used to close.

How strong is the evidence for each option?

The evidence is strongest that testosterone suppresses sperm production, solid but short-term that enclomiphene does not, and thinnest for TRT with HCG. That ranking matters more than any single headline result.

• TRT suppressing sperm production is well established, with consistent results across male contraception trials and clinical series (Crosnoe et al., 2013).
• Enclomiphene preserving sperm counts rests on randomized, double-blind trials, but the phase III studies ran 16 weeks (Kim et al., 2016). A review of the program concluded that its long-term effects remain unknown and that its impact on hypogonadal symptoms remained unknown, which limited the authors’ ability to recommend it as a therapy for hypogonadism (Rodriguez et al., 2016).
• TRT with HCG preserving fertility rests on a mechanism study in healthy volunteers (Coviello et al., 2005) and a retrospective review of 26 men (Hsieh et al., 2013). The results point the same way, but neither is a randomized trial of fertility outcomes.

What are the side effects of enclomiphene and HCG?

Both have side effects, and the data on them are thinner than the data on testosterone itself. The HCG product label lists headache, irritability, restlessness, depression, fatigue, edema, gynecomastia and pain at the injection site among its adverse reactions (Novarel label, DailyMed).

For enclomiphene, a 2016 review noted that its adverse effects had not been studied directly. It appeared well tolerated in the phase II and III trials, where reported side effects included elevated estradiol, headache and abdominal discomfort. The better-studied parent drug clomiphene, in women, commonly causes hot flushes, bloating, nausea, breast tenderness, visual disturbances and headaches, and the long-term effects of enclomiphene remain unknown (Rodriguez et al., 2016). On TRT with HCG, the testosterone side of the protocol still needs the usual monitoring, which in the Endocrine Society guideline includes hematocrit (Bhasin et al., J Clin Endocrinol Metab 2018).

Can you take TRT with enclomiphene?

The trials discussed here tested enclomiphene instead of testosterone, not on top of it, so they say nothing direct about TRT with enclomiphene taken together (Kim et al., 2016; Wiehle et al., 2014). The combination study cited on this page is a different situation: a retrospective series of 49 men who had become azoospermic or severely oligospermic on testosterone, treated with HCG plus clomiphene, tamoxifen, anastrozole or FSH to restart sperm production (Wenker et al., J Sex Med 2015).

Is clomiphene a cheaper alternative to enclomiphene?

Clomiphene is the older parent drug, and a 2016 review described it as a less expensive generic option. The same review noted that the two had not been compared directly, so it offered no head-to-head evidence on whether the cheaper drug performs the same. Clomiphene is a mixture of two isomers, zuclomiphene and enclomiphene (Rodriguez et al., 2016).

Status: Enclomiphene is not FDA-approved (OPSS, U.S. Dept. of Defense); clomiphene is approved only for ovulatory dysfunction in women and is used off label in men (clomiphene label, DailyMed); HCG is approved for indications that include some cases of male hypogonadotropic hypogonadism (Novarel label, DailyMed). What these status terms mean.

How long does it take to recover sperm production after TRT?

Most men recover sperm production after stopping testosterone, but the timeline runs from a few months to more than a year, and full recovery is not certain for everyone. An integrated analysis of hormonal male contraception trials found that the median man returned to a sperm concentration of 20 million per milliliter in about three to four months, roughly two thirds recovered by six months, about 90 percent by twelve months, and essentially all by twenty four months (Liu et al., Lancet 2006).

Recovery tended to be slower for men who used testosterone longer and for those whose sperm counts were lower to begin with (Liu et al., 2006), and a later review of men who used testosterone or anabolic steroids likewise tied longer exposure to a more prolonged recovery (McBride & Coward, 2016). The evidence on age is mixed: the integrated analysis linked older age with faster recovery, while the later review linked it with slower recovery, so age is not a reliable predictor either way (Liu et al., 2006; McBride & Coward, 2016). For men who have already been suppressed, published clinical experience describes HCG, sometimes with a SERM or FSH, to restart sperm production more actively (Wenker et al., 2015). Preserving fertility during therapy is easier than restoring it afterward.

Who should think about fertility before starting TRT?

Any man who might want biological children should raise fertility at the first visit, before a single dose of testosterone. Younger men and men without completed families have the most to protect, but plans change at any age. Sperm banking before starting is a straightforward insurance policy some men choose, and men who know they are done having children can reasonably consider testosterone alone.

Low testosterone itself can impair fertility in some men, and hypogonadotropic hypogonadism is a recognized, treatable cause of male-factor infertility (McBride & Coward, 2016), so the decision is not always a simple trade of symptoms against sperm.

How is a fertility-preserving protocol monitored?

A fertility-preserving protocol is monitored with periodic bloodwork and, when it matters, semen analysis, so the plan can be adjusted before a problem sets in. The most useful single step is a baseline semen analysis before starting, because there is no way to reconstruct it once therapy has begun.

Routine monitoring on testosterone centers on total testosterone, hematocrit and PSA, which both the Endocrine Society and the American Urological Association build into standard follow-up (Bhasin et al., 2018; AUA Testosterone Deficiency Guideline). Estradiol is not routine; the AUA guideline reserves it for men who develop breast tenderness or gynecomastia (AUA Testosterone Deficiency Guideline). On an HCG or enclomiphene plan, a provider may also follow LH and FSH, and a repeat semen analysis a few months in is the direct check that sperm production has been maintained.

How fertility planning fits into an online TRT visit

Fertility goals belong in the first live visit, before a protocol is chosen; our guide to how online TRT prescribing works covers that visit step by step.